MMP9 and hepatocellular carcinoma: It can reduce viability of the human liver carcinoma cells Hep-G2, inhibit adhesion, migration, and invasion of Hep-G2 cells in a concentration-dependent manner, inhibit matrix metalloproteinase-9 (MMP-9) expression, increase expression of metalloproteinase-1 tissue inhibitors and also reduce the expressions of vascular endothelial growth factor (VEGF) and NF-κB [69].